Compare Centene Corp (CNC) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Morgan Stanley — how do they compare? Centene Corp trades at $65 (market cap $32.89B), while Morgan Stanley trades at $215.3 (market cap $338.50B). The key difference: Morgan Stanley is far larger — about 10.3× Centene Corp's market cap, and Morgan Stanley pays a 2.14% dividend while Centene Corp pays none. Which is the better fit depends on your goals.
| CNC | MS | |
|---|---|---|
Market Cap | $32.89B | $338.50B |
Sector | Health | Financials |
52-Week High | $68.72 | $228.42 |
52-Week Low | $25.25 | $143.88 |
Enterprise Value | $21.93B | — |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene (CNC) trades at $65.77, up 2.48% with a bullish technical signal. Recent Q2 2026 earnings beat expectations with EPS of $2.51 versus $1.09 estimate, driven by margin recovery and cost control. Revenue grew to $194.78B in 2025, though net income was negative at -$6.67B. Valuation ratios are attractive with P/E of 8.06 and P/S of 0.16. Analyst consensus is strongly bullish with 61.37% buy ratings and a $70.36 price target.
Outlook is positive due to raised 2026 guidance and operational improvements, but risks include Medicaid membership softness and persistent negative margins. The stock offers value potential if profitability rebounds as projected, though investors should monitor medical cost trends and regulatory changes affecting government healthcare programs.
Morgan Stanley (MS) trades at $215.1, down 0.54% on the day, with a neutral technical signal and key support at $214. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.46 surpassing expectations of $2.89. Revenue growth accelerated to $66.0B in 2025, and net income margin improved to 25.56%. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.
The outlook remains positive with a consensus price target of $239.58, implying 11% upside. Strengths include robust profitability and strategic initiatives, but risks involve volatile cash flows from operations and high leverage. Analyst sentiment is bullish with 56% buy ratings, though investors should monitor debt levels and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
